About this trial
The goal of this clinical trial is to investigate the possible effects of tributyrin supplementation in patients with a first episode of acute pancreatitis. The main question it aims to answer is:
• The effect of oral tributyrin supplementation on the plasma endotoxin level
Participants will be randomized between two groups: intervention and control group. They will receive:
\- three times daily 4grams of micro-encapsulated granules of tributyrin, and the control group three times daily 4 grams of micro-encapsulated sunflower oil (i.e. placebo), for a total of 14 days
In total 92 adult patients with a first episode of acute pancreatitis will be included.
Eligibility criteria
Qualifiers
First episode of acute pancreatitis (AP)
Able to read and/or understand the study procedures
Able to give informed consent (or their legal representatives)
<24 hours after diagnosis of AP
Disqualifiers
Pancreatitis due to endoscopic retrograde cholangiopancreatography (ERCP), malignancy or trauma
Post-operative pancreatitis
Intra-operative diagnosis
Immunocompromised patients (history or current immunosuppressive treatment such as chemotherapy, radiotherapy, longer use of immunosuppressive medication or recent high doses, immunocompromised illness' such as AIDS, leukemia, lymphoma)
Trial design
Treatments tested in this trial
- Micro-encapsulated granules of tributyrin (intervention)
- Micro-encapsulated granules of sunflower oil (placebo)